The relationship between abdominal fat, glucose-regulated protein 78, and endometrial cancer
Keywords:
GRP78, abdominal fat, endometrial cancer GRP78, grasso addominale, cancro dell’endometrioAbstract
Background and aim: The adipocyte is the central element that integrates multiple metabolic and endocrine signals. This cell is the source for a multitude of bioactive peptides that play an essential role in endometrial cancer pathogenesis. The association of obesity with endometrial cancer is supported by Glucose-regulated protein 78 (GRP78), a marker of the stress endoplasmic reticulum (ER). GRP78 has an important anti-apoptotic role. Recent studies have demonstrated that GRP 78 plays an important role in the development, progression and tumor chemoresistance. The study aimed to identify a correlation between abdominal obesity, plasma GRP 78 level an d endometrial cancer. Methods: Two groups of patients were included in the study: group I – 44 patients diagnosed with endometrial cancer, group II – 44 patients without gynecological pathology or inflammatory disorders. After the performance of clinical examination and anthropometric measurements, abdominal fat was determined by dual X-ray absorptiometry and plasma GRP 78 level was measured. Results: Plasmatic level of GRP78 was significant higher in patients with endometrial cancer compared to the control group. Abdominal fat is in a positive linear correlation with the plasma GRP78 level (p<0.0001). Conclusions: The measurement GRP78 level associated with the determination of abdominal fat can be an useful predictor factor for endometrial cancer.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.